Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

被引：0
|
作者：
Remolina-Bonilla, Yuly A. [1 ]
Jimenez-Franco, Brenda [1 ]
Lam, Elaine T. [2 ]
Bourlon, Maria T. [3 ]
机构：
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
[2] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA
[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol & Med Oncol Dept, Mexico City, DF, Mexico
来源：
ONCOLOGY-NEW YORK | 2020年 / 34卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：171 / 174
页数：4
相关论文
共 50 条
  • [41] Nivolumab/pembrolizumabCNS immune-related adverse events: 2 case reports
    Reactions Weekly, 2021, 1838 (1) : 404 - 404
  • [42] Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
    Les, Inigo
    Martinez, Mireia
    Narro, Alicia
    Perez, Ines
    Sanchez, Cristina
    Punti, Laura
    Anaut, Pilar
    Eguiluz, Saioa
    Herrera, Alberto
    Dominguez, Severina
    ANNALS OF MEDICINE, 2021, 53 (01) : 762 - 769
  • [43] Nivolumab/pembrolizumabNeurological immune-related adverse events: 4 case reports
    Reactions Weekly, 2023, 1977 (1) : 235 - 235
  • [44] Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma
    Mehta, Anurag
    Gupta, Arjun
    Hannallah, Franck
    Koshy, Thomas
    Reimold, Sharon
    MELANOMA RESEARCH, 2016, 26 (03) : 319 - 320
  • [45] Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
    J Gao
    Q He
    S Subudhi
    A Aparicio
    A Zurita-Saavedra
    D H Lee
    C Jimenez
    M Suarez-Almazor
    P Sharma
    Oncogene, 2015, 34 : 5411 - 5417
  • [46] Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
    Gao, J.
    He, Q.
    Subudhi, S.
    Aparicio, A.
    Zurita-Saavedra, A.
    Lee, D. H.
    Jimenez, C.
    Suarez-Almazor, M.
    Sharma, P.
    ONCOGENE, 2015, 34 (43) : 5411 - 5417
  • [47] COMBINED NIVOLUMAB PLUS IPILIMUMAB THERAPY CAUSE HIGHER GRADE AND EARLIER IMMUNE-RELATED ADVERSE EVENTS HEPATITIS OCCURRENCE THAN SINGLE AGENT THERAPY
    Nagashima, Hiroyuki
    Sagawa, Tamotsu
    Hirakawa, Masahiro
    Waga, Eriko
    Fujikawa, Koshi
    Takahashi, Yasuo
    GASTROENTEROLOGY, 2020, 158 (06) : S1307 - S1307
  • [48] Patient Voices in Rheumatic Immune-related Adverse Events
    Corps, Kara N.
    Terry, Oliver
    Lopez-Olivo, Maria A.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2024, 50 (02) : 241 - 254
  • [49] Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
    Bernhard Scheiner
    Matthias Pinter
    memo - Magazine of European Medical Oncology, 2022, 15 : 58 - 61
  • [50] Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
    Scheiner, Bernhard
    Pinter, Matthias
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (01) : 58 - 61
12345